Mac-2 binding protein glycosylation isomer as a potential biomarker of hepatocellular carcinoma in HCV-cured patients

ObjectiveMac-2 binding protein glycosylation isomer (M2BPGi) is produced in the extracellular matrix and serves as an indicator of hepatic stellate cell activation. Assessing M2BPGi levels could aid in predicting hepatocellular carcinoma (HCC) in individuals with hepatitis C virus (HCV). The objecti...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Liver Journal 2024-11, Vol.14 (1), p.84-10
Main Authors: Hanafy, Amr Shaaban, Abdelaziz, Khalid Ali Muftah, Mohammad, Fedaa Nabil, Ibrahim, Amr Samir
Format: Article
Language:English
Subjects:
Abdomen
Biomarkers
Creatinine
Diabetes
HCC
HCV
Health care
Hemoglobin
Hepatitis B
Hepatitis C
Infections
Liver cancer
Liver cirrhosis
Liver diseases
M2BPGi
Monoclonal antibodies
Proteins
Statistical analysis
Ultrasonic imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveMac-2 binding protein glycosylation isomer (M2BPGi) is produced in the extracellular matrix and serves as an indicator of hepatic stellate cell activation. Assessing M2BPGi levels could aid in predicting hepatocellular carcinoma (HCC) in individuals with hepatitis C virus (HCV). The objective of this study was to evaluate the usefulness of M2BPGi as a biomarker for HCC in HCV patients and its association with disease severity and progression.MethodsThis study included patients who were cured of chronic hepatitis C virus. The patients were divided into three subgroups: HCV without cirrhosis, HCV with cirrhosis, and HCV with HCC. These subgroups were then compared to a subgroup of healthy volunteers. In addition to routine laboratory investigations, M2BPGi levels were measured in all the enrolled subjects.ResultsThe level of serum M2BPGi was significantly greater in the HCV with cirrhosis and HCC groups than in the control group (P 
ISSN:2090-6218
2090-6226
DOI:10.1186/s43066-024-00389-6